Cargando…

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

BACKGROUND: Fatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuhashi, Masato, Sakuma, Ichiro, Morimoto, Takeshi, Higashiura, Yukimura, Sakai, Akiko, Matsumoto, Megumi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296623/ https://www.ncbi.nlm.nih.gov/pubmed/32539832 http://dx.doi.org/10.1186/s12933-020-01061-0

Ejemplares similares

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
por: Furuhashi, Masato, et al.
Publicado: (2020)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2020)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2020)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study
por: Saito, Norie, et al.
Publicado: (2021)

Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals
por: Tanaka, Marenao, et al.
Publicado: (2022)

Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria
por: Tanaka, Marenao, et al.
Publicado: (2020)

Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells
por: Yamamoto, Tokunori, et al.
Publicado: (2016)

Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication
por: Furuhashi, Masato, et al.
Publicado: (2022)

High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population
por: Higashiura, Yukimura, et al.
Publicado: (2022)

Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication
por: Furuhashi, Masato, et al.
Publicado: (2022)

Differential regulation of hypoxanthine and xanthine by obesity in a general population
por: Furuhashi, Masato, et al.
Publicado: (2020)

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases
por: Furuhashi, Masato, et al.
Publicado: (2015)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters
por: Furuhashi, Masato, et al.
Publicado: (2016)

High expression of FABP4 and FABP6 in patients with colorectal cancer
por: Zhang, Yaqin, et al.
Publicado: (2019)

Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
por: Kim, Sang-Yong, et al.
Publicado: (2022)

Comparison of the prognostic values of three calculation methods for echocardiographic relative wall thickness in acute decompensated heart failure
por: Yamaguchi, Satoshi, et al.
Publicado: (2019)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation
por: Ikedo, Taichi, et al.
Publicado: (2017)

FABP3, FABP4, and heart rate variability among patients with chronic schizophrenia
por: Hung, Wei-Chin, et al.
Publicado: (2023)

Independent links between plasma xanthine oxidoreductase activity and levels of adipokines
por: Furuhashi, Masato, et al.
Publicado: (2019)

Prognostic Impact of Early Changes in Serum Chloride Concentrations Among Hospitalized Acute Heart Failure Patients　― A Retrospective Cohort Study ―
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport
por: Goto, Moritaka, et al.
Publicado: (2018)

Anagliptin promotes apoptosis in mouse colon carcinoma cells via MCT-4/lactate-mediated intracellular acidosis
por: Li, Qi, et al.
Publicado: (2022)

Expression and enhancement of FABP4 in septoclasts of the growth plate in FABP5-deficient mouse tibiae
por: Bando, Yasuhiko, et al.
Publicado: (2021)

Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials
por: Nezu, Uru, et al.
Publicado: (2013)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Mechanism of lipid‐lowering action of the dipeptidyl peptidase‐4 inhibitor, anagliptin, in low‐density lipoprotein receptor‐deficient mice
por: Yano, Wataru, et al.
Publicado: (2016)

FABP4 and I-FABP Levels in Pregnant Women Are Associated with Body Mass Index but Not Gestational Diabetes
por: Vorobjova, Tamara, et al.
Publicado: (2022)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

Low urine pH predicts new onset of diabetes mellitus during a 10‐year period in men: BOREAS‐DM1 study
por: Higashiura, Yukimura, et al.
Publicado: (2020)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio, Shinya, et al.
Publicado: (2015)

Antiatherosclerotic Phenotype of Perivascular Adipose Tissue Surrounding the Saphenous Vein in Coronary Artery Bypass Grafting
por: Mikami, Takuma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qogfgtof2o1inm9hgd27v78eg1